HC Wainwright reaffirmed their buy rating on shares of IMV (NYSE:IMV) in a research report report published on Monday, AnalystRatings.com reports. They currently have a $11.50 target price on the stock.
Several other equities research analysts have also recently weighed in on IMV. Wells Fargo & Co started coverage on IMV in a research note on Monday, October 28th. They set a market perform rating for the company. Zacks Investment Research cut IMV from a buy rating to a hold rating in a research note on Saturday, October 26th. Finally, Raymond James set a $10.00 target price on IMV and gave the stock an outperform rating in a research note on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. IMV has a consensus rating of Buy and an average price target of $9.60.
IMV stock traded up $0.08 during trading on Monday, hitting $2.49. 5,700 shares of the company’s stock were exchanged, compared to its average volume of 19,652. The business has a 50-day moving average price of $2.66 and a two-hundred day moving average price of $3.12. IMV has a 52-week low of $2.25 and a 52-week high of $7.07.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada increased its position in IMV by 3.6% during the second quarter. Royal Bank of Canada now owns 98,676 shares of the company’s stock worth $288,000 after buying an additional 3,453 shares during the period. Morgan Stanley increased its position in IMV by 260.5% during the second quarter. Morgan Stanley now owns 90,368 shares of the company’s stock worth $264,000 after buying an additional 65,300 shares during the period. Bank of Montreal Can increased its position in IMV by 17.5% during the second quarter. Bank of Montreal Can now owns 88,889 shares of the company’s stock worth $260,000 after buying an additional 13,228 shares during the period. Hartford Financial Management Inc. increased its holdings in shares of IMV by 9.6% in the third quarter. Hartford Financial Management Inc. now owns 38,098 shares of the company’s stock valued at $94,000 after purchasing an additional 3,348 shares during the period. Finally, Citadel Advisors LLC acquired a new position in shares of IMV in the second quarter valued at approximately $37,000.
IMV Company Profile
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Further Reading: Are sell-side analysts objective?
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.